IGM Biosciences (IGMS)
(Delayed Data from NSDQ)
$9.27 USD
-0.07 (-0.75%)
Updated May 13, 2024 04:00 PM ET
After-Market: $9.27 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
IGMS 9.27 -0.07(-0.75%)
Will IGMS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IGMS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IGMS
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings
IGMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for IGMS
Bank of America Securities Sticks to Their Hold Rating for IGM Biosciences (IGMS)
IGM Biosciences (IGMS) Gets a Buy from Truist Financial
Short Report: Wayfair bears scrambling as pre-earnings build-up is foiled
IGM Biosciences: Unlikely To Move The Needle Again In 2024
IGM Biosciences Inc (IGMS) Q1 2024 Earnings: Aligns with EPS Projections Amidst Clinical ...